News & Updates
Read about what’s been going on at AlgoDx
Early prediction of sepsis in intensive care patients using the machine learning algorithm NAVOY®, a prospective randomized clinical validation study – manuscript accepted for publication in Journal of Critical Care
August 16th, 2023.
AlgoDx winner of Swecare Rising Star Award 2023
April 27th, 2023.
Algodx has been awarded the Swecare Rising Star Award 2023. The prize is awarded to the company that “has managed to demonstrate successful export initiatives of Swedish products, services and knowledge that improve people’s health.”. David Becedas, founder and CEO, received the award from the Minister of Social Affairs Jakob Forssmed at a ceremony in Stockholm. Read more here.
AlgoDx announces FDA acceptance of De Novo application for first ICU sepsis prediction algorithm
April 13th, 2023.
AlgoDx announces today that the US Food and Drug Administration has accepted for review the company’s De Novo application for NAVOY® Sepsis, a clinical decision support software intended to assist healthcare providers at intensive care units with predicting sepsis in adult ICU patients. Read more here.
NAVOY® can reduce occupancy rates, save lives and reduce costs for U.S. hospitals
March 7th, 2023.
The NAVOY® health economic abstract titled The Use of a Machine Learning Algorithm for Early Detection of Sepsis Can Reduce Occupancy Rates, Save Lives, and Reduce Costs for US Hospitals has been accepted as a poster presentation to ISPOR 2023 taking place May 7-10. ISPOR 2023 will be held in-person at the Boston Conference & Exhibition Center, Boston, Massachusetts, read more here.
Top-line results from the NAVOY® clinical validation trial presented at SCCM
January 22nd, 2023.
Successful clinical validation results have been presented by Fredrik Sjövall MD, PhD, DEAA, EDIC at the 2023 SCCM Critical Care Congress in San Francisco. In our prospective study, 304 intensive care patients, of which 44 patients had been diagnosed with Covid-19, were monitored using NAVOY® during their ICU stay. The trial (NCT04570618) is the largest randomized clinical trial with a ML sepsis predictor ever conducted, and the first study that clinically validates a sepsis predictor against the consensus definitions for sepsis and septic shock (Sepsis-3).
AlgoDx recognized as one of the best startups in Sweden
October 20th, 2022.
AlgoDx has been recognized in the Swedish tech magazine Ny Teknik’s 33-listan, a long-running prestigious listing of the best technology start-ups in Sweden. Ny Teknik lists startups with international traction and potential to disrupt their respective industries. Read more here (in Swedish).
NAVOY® clinical trial abstract accepted at Society of Critical Care Medicine Congress in San Francisco, California
October 14th, 2022.
An abstract with study result data from the largest randomised clinical trial ever conducted with a sepsis predictor in ICU has been accepted for presentation at the 2023 Society of Critical Care Medicine Congress. The SSCM Congress will be held January 21-24 in San Francisco, California. Read more here.
NAVOY® health economic model to be presented at ISPOR Europe 2022
September 28th, 2022.
3 hours earlier sepsis detection in ICU using NAVOY® and intervention with antibiotics leads to improved patient outcomes and reduced hospitalisation costs. Health economic research led by the Institute for Health Economics will be presented at Europe’s leading HE congress, ISPOR in Vienna November 6-9, 2022, poster title: The Potential Cost and Cost-Effectiveness Impact of Using Machine Learning Sepsis Prediction Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden and the United Kingdom. Read more here.
Real-world implementation of AlgoDx’s NAVOY® nominated to the Athena Prize
September 15th, 2022.
The real-world integration of NAVOY® with the ICUs at the Southern General Hospital in Stockholm has been nominated as finalist to the prestigious Athena Prize. The Athena Prize each year awards research and innovations created through collaboration between healthcare, academia and business. Read more here (in Swedish).
AlgoDx – Startup of the Year
June 30th, 2022.
AlgoDx has been awarded Best startup of the year by OVHcloud, a leading cloud computing provider. This prestigious award accentuates the cutting-edge technology that has been developed and deployed on the cloud by AlgoDx. Read more here.
AlgoDx joins Innovation Collaborative as a founding member to bring AI/ML to the front lines of healthcare
June 9th, 2022.
NAVOY® reduces the cost per ICU patient and will potentially have a substantial cost-saving and life-saving impact for ICU departments and health system.
April 26th, 2022.
Clinical validation of NAVOY® in intensive care presented at the International Symposium on Intensive Care & Emergency Medicine
March 22nd, 2022.
Successful clinical validation results have been presented at the 41st International Symposium on Intensive Care & Emergency Medicine. In our prospective study, 304 intensive care patients (of which 44 patients had been diagnosed with Covid-19) were monitored using NAVOY® during their ICU stay. The trial (NCT04570618) is the largest randomized clinical trial with a machine learning sepsis predictor ever conducted, and the first study that clinically validates a sepsis predictor against the Sepsis-3 criteria. Read more here.
NAVOY® in real-world use at the Southern General Hospital
Feb 23rd, 2022.
Swedish National Public Radio has reported on the installation of NAVOY® at the ICUs at Southern General Hospital in Stockholm, Sweden. Listen here (in Swedish).
AlgoDx partners with Takeda Pharma to develop IBD prediction algorithm for out-patient care
Feb 2nd, 2022.
AlgoDx gets late-breaking intensive care abstract accepted
Jan 25th, 2022.
AlgoDx announces that an abstract on clinical data of its ML-based sepsis predictor NAVOY® has been accepted for a poster presentation at ISICEM. Read more here.
Uppsala University reports about the groundbreaking research lead by our Director of AI & Biostatistics,
Dr Inger Persson
Oct 28th, 2021.
Uppsala University narrates the story on how NAVOY® was born, where a combination of AI and existing patient data helps healthcare professionals detect sepsis at an early stage. Read more here.
Proof-of-Concept Study of NAVOY® published in JMIR
Oct 12th, 2021.
Our paper “A Machine Learning Sepsis Prediction Algorithm for Intended Intensive Care Unit Use (NAVOY Sepsis): Proof-of-Concept Study” has been published in JMIR Formative Research. Read more here.
The development of AlgoDx’s NAVOY® nominated to the Athena Prize
Sep 18th, 2021.
AlgoDx’s clinical development programme for NAVOY® has been nominated as finalist to the prestigious Athena Prize. The Athena Prize each year awards research and innovations created through collaboration between healthcare, academia and business. Read more here.
Completion of patient enrolment in clinical validation study of NAVOY®
Sep 16th, 2021.
AlgoDx announces the completion of the patient enrolment in the world’s largest randomized clinical trial with a sepsis prediction algorithm (NCT04570618).
Meet Dr. Inger Persson, our Director AI & Biostatistics, at Vitalis eConference
May 18th, 2021.
Meet Dr Inger Persson, our Director AI & Biostatistics, who will be presenting at Vitalis eConference – Using Machine Learning To Predict Sepsis In Intensive Care. Read more here.
AlgoDx’s NAVOY® gets CE mark for AI-powered sepsis prediction software
May 4th, 2021.
AlgoDx today announces the obtention of the CE mark for NAVOY® Sepsis. This medical device software is intended to assist medical staff at Intensive Care Units (ICU) to predict sepsis in adult ICU patients. Read press release here.
AlgoDx receives grant from Sweden’s Innovation Agency
April 28th, 2021.
AlgoDx receives the Innovative Startups grant by Vinnova aimed to develop scalable solutions that contribute to sustainable growth in a global market. This grant will allow AlgoDx to accelerate the development of the AlgoDx Cloud Platform for the integration of algorithm diagnostics and data-driven precision medicine in Electronic Health Record systems for Intensive Care.
April 7th, 2021.
November 17th, 2020.
We are proud to see AlgoDx among the top startups of the 1st version of the European AI Startup Landscape, an initiative led by AI Sweden, UnternehmerTUM, Hub France AI, Ignite Sweden and RISE Research Institutes of Sweden with the objective to foster and accelerate AI in Europe. Check out the European AI Startup Landscape here.
August 24th, 2020.
AlgoDx today announces the obtention of regulatory approval from the Swedish Medical Products Agency to start a sepsis prediction study at an Intensive Care Unit in Sweden. The study has previously been approved by the National Ethics Committee through an expedited review for research that has potential to provide benefit for the treatment and prevention of Covid-19, given that sepsis is a common complication in connection with Covid-19. Read press release here.
April 6th, 2020.
Sweden’s Innovation Agency Vinnova has, through their SweLife and Medtech4Health programme, awarded a grant of 3 MSEK to AlgoDx together with Skåne University Hospital and Uppsala University. Read press release here.